Skip to Main content Skip to Navigation
New interface
Journal articles

Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey

Abstract : Background: Cardiovascular toxicity has become a challenging issue during cancer therapy. Nonetheless, there is a lack of consensual guidelines for their management. We aimed to determine the current practices of oncologists regarding cardiovascular toxicity related to anthracyclines, trastuzumab and angiogenic inhibitors and to gather their opinions on the development of cardio-oncology programs. Methods: A cross-sectional declarative study was submitted to French oncologists in the form of an individual, structured questionnaire. Results: A total of 303 oncologists responded to the survey. Ninety-nine percent of oncologists prescribed cardiotoxic therapies, including anthracyclines (83%), trastuzumab (51%) and other angiogenic inhibitors (64%). The method adopted for managing cardiovascular toxicity was based on guidelines from expert oncology societies for only 35% of oncologists. None was aware of recommendations from expert cardiology societies. Prescription of pre-, peri- and post-therapy cardiovascular assessment was inconsistent and significantly less frequent for all classes of angiogenic inhibitors than for anthracyclines and trastuzumab (P < 0.0001). Relative to pre-therapy assessment, post-therapy assessment was prescribed significantly less often for all cancer therapies (P < 0.0001). Attitudes regarding the onset of left ventricular dysfunction were much more inconsistent when angiogenic inhibitors were involved. Additionally, the management of hypertension and QT prolongation was also inconsistent. Finally, 88% of oncologists supported projects of cardio-oncology programs development. Conclusions:Practices of oncologists are disparate in the field of cardiovascular toxicity. This finding underlines the complexity of managing many different situations and the need for distribution of formal guidelines from oncology and cardiology expert societies. The development of personalized cardio-oncology programs seems essential.
Complete list of metadata

Cited literature [25 references]  Display  Hide  Download
Contributor : Françoise DIGNAT-GEORGE Connect in order to contact the contributor
Submitted on : Wednesday, May 23, 2018 - 10:41:01 AM
Last modification on : Thursday, August 25, 2022 - 9:14:34 AM
Long-term archiving on: : Friday, August 24, 2018 - 8:22:18 PM


Files produced by the author(s)




Ludovic Jovenaux, Jennifer Cautela, Noémie Resseguier, Michele Pibarot, Myriam Taouqi, et al.. Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. International Journal of Cardiology, 2017, 241, pp.387-392. ⟨10.1016/j.ijcard.2017.02.154⟩. ⟨hal-01798104⟩



Record views


Files downloads